UroGen Pharma Ltd. PE Ratio
The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
- UroGen Pharma Ltd. pe ratio for the quarter ending 2026-06-30 was -18.42, a change of -14.34 year-over-year.
- UroGen Pharma Ltd. pe ratio for the quarter ending 2026-03-31 was -6.57, a change of -2.89 year-over-year.
- UroGen Pharma Ltd. pe ratio for the quarter ending 2025-12-31 was -7.38, a change of -3.83 year-over-year.
- UroGen Pharma Ltd. pe ratio for the quarter ending 2025-09-30 was -5.67, a change of -1.02 year-over-year.
- UroGen Pharma Ltd. pe ratio for fiscal 2026 was -18.42.
- UroGen Pharma Ltd. pe ratio for fiscal 2025 was -7.38, a change of -3.83 from fiscal 2024.
- UroGen Pharma Ltd. pe ratio for fiscal 2024 was -3.54, a change of 1.22 from fiscal 2023.
- UroGen Pharma Ltd. pe ratio for fiscal 2023 was -4.77, a change of -2.9 from fiscal 2022.
- Available history
- 2017-12-31 to 2026-06-30
- Data captured
Historical PE Ratio
Annual PE Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |